CorVel (NASDAQ:CRVL) Director Sells $110,449.02 in Stock

CorVel Corp. (NASDAQ:CRVL) Director R Judd Jessup sold 1,562 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $70.71, for a total value of $110,449.02. Following the completion of the transaction, the director owned 117,083 shares in the company, valued at $8,278,938.93. The trade was a 1.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

R Judd Jessup also recently made the following trade(s):

• On Thursday, August 27th, R Judd Jessup sold 1,262 shares of CorVel stock. The stock was sold at an average price of $70.64, for a total transaction of $89,147.68.

CorVel Price Performance

Shares of CorVel stock opened at $69.24 on Monday. CorVel Corp. has a 12-month low of $44.83 and a 12-month high of $93.45. The company has a market capitalization of $3.53 billion, a price-to-earnings ratio of 30.77 and a beta of 0.98. The firm’s 50-day moving average price is $63.41 and its two-hundred day moving average price is $58.31.

CorVel (NASDAQ:CRVL) last issued its earnings results on Tuesday, August 4th. The business services provider reported $0.63 EPS for the quarter. The company had revenue of $259.93 million during the quarter. CorVel had a net margin of 11.72% and a return on equity of 29.92%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CRVL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in CorVel by 0.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,961 shares of the business services provider’s stock valued at $1,640,000 after buying an additional 115 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of CorVel by 0.9% during the second quarter. The Manufacturers Life Insurance Company now owns 15,918 shares of the business services provider’s stock worth $1,636,000 after acquiring an additional 139 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its position in shares of CorVel by 18.9% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,228 shares of the business services provider’s stock worth $77,000 after acquiring an additional 195 shares during the last quarter. Benjamin Edwards Inc. lifted its stake in shares of CorVel by 6.0% in the fourth quarter. Benjamin Edwards Inc. now owns 3,843 shares of the business services provider’s stock worth $260,000 after acquiring an additional 218 shares during the period. Finally, Rockefeller Capital Management L.P. boosted its holdings in CorVel by 66.9% in the fourth quarter. Rockefeller Capital Management L.P. now owns 574 shares of the business services provider’s stock valued at $39,000 after acquiring an additional 230 shares during the last quarter. 51.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on CRVL shares. Wall Street Zen raised CorVel from a “hold” rating to a “buy” rating in a report on Saturday, May 30th. Weiss Ratings upgraded CorVel from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 16th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

CorVel Company Profile

CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.

The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).